This specific feature may be of interest in drug discovery in a time when adenosine receptors are gaining momentum after the approval (in Japan and the USA) of istradefylline, a selective A2AR antagonist, as adjuvant therapy in Parkinson’s disease [30,31,32,33,34]. The gene discussed is ADORA2A; the disease is Parkinson disease.